Lipocine (NASDAQ:LPCN – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They presently have a $4.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 80.59% from the stock’s previous close.
A number of other equities analysts also recently issued reports on LPCN. Weiss Ratings downgraded shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $4.00.
Read Our Latest Stock Analysis on LPCN
Lipocine Price Performance
Lipocine (NASDAQ:LPCN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. As a group, equities research analysts expect that Lipocine will post -1.91 earnings per share for the current year.
Institutional Trading of Lipocine
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new position in Lipocine during the first quarter valued at $998,000. Stempoint Capital LP bought a new position in shares of Lipocine during the first quarter valued at approximately $1,282,000. ADAR1 Capital Management LLC purchased a new stake in Lipocine in the first quarter worth $185,000. Eversept Partners LP bought a new stake in Lipocine during the 1st quarter valued at about $2,357,000. Finally, Exome Asset Management LLC bought a new position in Lipocine in the first quarter worth approximately $486,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.
Lipocine Company Profile
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Lipocine
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
- 3 Retail Dips Backed by Rising Consumer Demand
- 3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
